Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery
NCT ID: NCT03520829
Last Updated: 2018-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2018-01-10
2020-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The existing reverse planning systems, although they have progressed considerably in recent years, produce results that are still lower than those achieved by an expert.
Conventionally, an experienced dosimetric planner will act mainly on the coordinates of the position of the isocenters, on the size of the collimators, sector by sector, and on the irradiation time of each isocenters. In theory, the combination of these variables provides access to billions of combinatorics whose diversity far exceeds the computational capabilities of the human mind. The dosimetric planner therefore uses a very small part of the spectrum of possible patterns by always reproducing a limited number of empirical solutions.
The company Intuitive Therapeutics has developed a new mathematical algorithm which can automatically test in a very short time all the combinatorial possibilities and converge very quickly to the solution that best meets the clinical, anatomical and dosimetric objectives defined by the neurosurgeon. The quick processing of the system also allows the operator to modify the constraints to refine the proposed result in real time.
The demonstration of the reality of the performances of this algorithm would give the ability to even inexperienced users to develop high performance planning for the benefit of the patient in terms of optimizing the efficacy / toxicity ratio of the radiosurgery treatment results
The primary objective is to evaluate comparatively the quality of the schedules produced by the algorithm developed by the company Innovative Therapeutics to those produced by an expert who carried out more than 15000 dosimetric plannings and radiosurgical interventions.
The main criterion of comparison is the Paddick index.
The secondary criteria for comparison are:
* Compliance index
* selectivity index
* Gradient index
* Maximum, minimum, average dose at risk structures
* Dose distribution in the target volume
* Treatment time (at equal source activity)
* Time of realization of the planning
It was chosen to treat patients with vestibular Schwannoma OR multiple brain metastases (\> 5) treated in single session by Gamma Knife OR para-optic meningioma in hypo-fractionated treatment on Gamma Knife with restraint mask with inclusion of visual paths in the target volume planning.
The aim of the study is to show at least the non-inferiority of this new method compared to the expert user based on the Paddick Index. This index has continuous values between 0 and 1, 0 being the worst case and 1 being the ideal solution. In order to define the sample size needed for each pathology, a pilot phase is required. This phase can be performed retrospectively using treatments already defined by the expert user. This pilot phase will allow us to identify the difference that can be expected between the index values and the variability of this difference. Based on these values we will be able to determine the size of the sample allowing us to statistically test the non-inferiority, or even the superiority of this new device. The number of cases to be included during the pilot phase should be at least ten cases and a maximum of thirty cases. The choice of the number of cases to be integrated during this pilot phase will depend on the homogeneity of the differences obtained on the first cases. These values will allow us to calculate the size of the samples necessary for the study of non-inferiority as well as for the study of superiority. Depending on the calculated sizes samples we will make a choice to ensure that this study takes place in the expected duration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
NCT02005614
Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy
NCT03534050
A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)
NCT01821443
Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
NCT04545814
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
NCT03903419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient treated for Gamma Knife
Intuitive Plan
dosimetric planning software
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intuitive Plan
dosimetric planning software
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient treated for Gamma Knife
* Patient who has benefited or needs Gamma-Knife radiosurgical treatment
* Patient affiliated to a social protection scheme.
* Patient having understood the information notice and expressed his non opposition.
Exclusion Criteria
* Patient with a contraindication to radiosurgical treatment (previous treatment with cerebral radiotherapy)
* Pregnant and lactating women
* Simultaneous participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
* Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults unable to express their consent.
* Patient expressing opposition to participation in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Olivier ARNAUD, Director
Role: STUDY_DIRECTOR
ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Hôpitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02753-50
Identifier Type: REGISTRY
Identifier Source: secondary_id
2017-52
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.